RBC Capital Previews Regeneron Pharma (REGN): 'Deep Dive Suggests Plenty Of Reasons For Optimism'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $943.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
